ArticleNature communications2022

TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma.

Tatiana Erazo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.